AGT and chronic myelogenous leukemia, BCR-ABL1 positive: Despite the high success rate of CML treatment with imatinib, it has been reported that a significant proportion of CML patients develop drug resistance due to mutations such as T315I.19 Against this background, AGT may be effective against CML drug resistance because it exerts an antitumor effect through a different mechanism of action than imatinib.